Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

31.99USD
26 Dec 2014
Price Change (% chg)

$0.67 (+2.14%)
Prev Close
$31.32
Open
$31.30
Day's High
$32.04
Day's Low
$31.30
Volume
139,098
Avg. Vol
223,967
52-wk High
$33.03
52-wk Low
$21.34

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals... (more)

Overall

Beta: 1.09
Market Cap (Mil.): $2,279.24
Shares Outstanding (Mil.): 71.25
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): 47.72 38.36 38.84
EPS (TTM): 0.67 -- --
ROI: 5.37 18.99 18.26
ROE: 5.58 19.74 19.12
Search Stocks

Fitch: M&A Drives Negative Global Pharma Rating Outlook for 2015; Sector Fundamentals Intact

(The following statement was released by the rating agency) Link to Fitch Ratings' Report: 2015 Outlook: Global Pharmaceuticals (Strategic Industry Evolution to Continue; M&A Reduces Rating Headroom) http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=834168 LONDON, December 11 (Fitch) Fitch Ratings believes 2015 will be a transitional year for global pharma companies as they continue to evolve their business models and position themselves for structural changes in the indu

11 Dec 2014

Impax Labs on the hunt after striking two deals worth $700 million

- Impax Laboratories Inc said it was on the hunt for further deals - and would consider a so-called "tax inversion" transaction - after its acquisition of two privately held Pennsylvania drugmakers for $700 million.

09 Oct 2014

UPDATE 2-Impax Labs on the hunt after striking two deals worth $700 mln

Oct 9 - Impax Laboratories Inc said it was on the hunt for further deals - and would consider a so-called "tax inversion" transaction - after its acquisition of two privately held Pennsylvania drugmakers for $700 million.

09 Oct 2014

CORRECTED-UPDATE 1-Impax buys anti-allergy injection makers for $700 mln

(Corrects paragraph 5 to say the EpiPen is produced my Mylan Inc, not Pfizer Inc)

09 Oct 2014

Impax buys two private drugmakers for $700 mln

Oct 9 - Impax Laboratories Inc said it bought two privately held drugmakers for $700 million to gain access to seven generic drugs.

09 Oct 2014

Impax Parkinson's drug future shaky as FDA flags factory issues

- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.

29 Jul 2014

UPDATE 2-Impax Parkinson's drug future shaky as FDA flags factory issues

* Analysts say concerns may delay review date of Parkinson's drug

29 Jul 2014

U.S. FDA raises concerns about Impax's Taiwanese plant

July 29 - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.

29 Jul 2014

Impax Labs get subpoena in price fixing probe

- - Impax Laboratories said it was subpoenaed by the Connecticut Attorney General regarding an investigating into possible price fixing of its generic heart drug, digoxin.

15 Jul 2014

Impax Labs get subpoena in price fixing probe

- - Impax Laboratories said it was subpoenaed by the Connecticut Attorney General regarding an investigating into possible price fixing of its generic heart drug, digoxin.

15 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks